PXD018571 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | A mass spectrometry-based proteome map of drug action in lung cancer cell lines Part 3 |
Description | Mass spectrometry-based discovery proteomics is an essential tool for the proximal read-out of cellular drug action. Here, we used a robust proteomic workflow to rapidly and systematically profile the proteomes of five cell lines in response to > 50 drugs. We found that aggregating millions of quantitative protein-drug associations substantially improved the mechanism of action (MoA) deconvolution of single compounds. For example, MoA specificity increased after removal of proteins which frequently responded to drugs and the aggregation of proteome changes across multiple cell lines resolved compound effects on proteostasis. These characteristics were further leveraged to demonstrate efficient target identification of protein degraders. Moreover, we followed up on selected proteomic findings and showed that the inhibition of mitochondrial function is an off-target mechanism of the clinical MEK inhibitor PD184352 and that Ceritinib, an FDA approved drug in lung cancer, modulates autophagy. Overall, this study demonstrates that large-scale proteome perturbation profiling can be a useful addition to the drug discovery toolbox. |
HostingRepository | PRIDE |
AnnounceDate | 2024-10-22 |
AnnouncementXML | Submission_2024-10-22_05:10:50.546.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Benjamin Ruprecht |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | monohydroxylated residue; acetylated residue; iodoacetic acid derivatized residue |
Instrument | Q Exactive HF |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2020-04-15 01:15:12 | ID requested | |
1 | 2020-08-16 22:28:23 | announced | |
2 | 2020-09-28 00:28:43 | announced | 2020-09-28: Updated publication reference for PubMed record(s): 32690943. |
⏵ 3 | 2024-10-22 05:10:58 | announced | 2024-10-22: Updated project metadata. |
Publication List
Ruprecht B, Di Bernardo J, Wang Z, Mo X, Ursu O, Christopher M, Fernandez RB, Zheng L, Dill BD, Wang H, Xu Y, Liaw A, Mortison JD, Siriwardana N, Andresen B, Glick M, Tata JR, Kutilek V, Cornella-Taracido I, Chi A, A mass spectrometry-based proteome map of drug action in lung cancer cell lines. Nat Chem Biol, 16(10):1111-1119(2020) [pubmed] |
10.1038/s41589-020-0572-3; |
Keyword List
submitter keyword: Mass spectrometry,Drug discovery, Proteomics, Perturbation profiling |
Contact List
An Chi |
contact affiliation | Merck |
contact email | An_Chi@merck.com |
lab head | |
Benjamin Ruprecht |
contact affiliation | Merck |
contact email | Benjamin.Ruprecht@merck.com |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/08/PXD018571 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD018571
- Label: PRIDE project
- Name: A mass spectrometry-based proteome map of drug action in lung cancer cell lines Part 3